Adult mesenchymal stem cells (MSCs) were previously described as multipotent cells that could differentiate into bone, cartilage, muscle, and other mesenchymal tissues. New information suggests that MSCs can be found in every tissue of the body because they function as perivascular cellsVpericytesVfound outside all blood vessels. When these vessels break or are inflamed, pericytes are detached and form MSCs, which are activated by their local microenvironment of injury. Such MSCs function to secrete powerful immune-modulatory and regenerative agents; more than 450 clinical trials are now ongoing, covering a huge spectrum of clinical conditions. How such activated MSCs affect menstrual cycle, menopause, or osteotrophic cancers has only recently been studied. This article outlines these issues and challenges the scientific and medical community to use this newfound knowledge to uncover new clinical logics and medial solutions for women.
very tissue in the human body houses adult mesenchymal stem cells (MSCs). What are they? What do they do? How can they be managed to enhance women's health care? Some of the answers to these questions are now emerging. As a component of my invitation to deliver the 2014 NAMS/PfizerVWulf H. Utian Endowed Lecture, I offer this article as a treatise on the latest information about MSCs and as a challenge to the scientific and medical community to use MSC technology to improve healthcare delivery to women.
MESENCHYMAL STEM CELLS The old
In the late 1980s, I formulated a cell-based therapy working hypothesis, the outline of which is presented in Figure 1 . 1<3 Indeed, studies have shown that marrow-derived or adipose-derived MSCs in cell culture can be induced into differentiation lineage pathways that sustain the formation of bone, cartilage, muscle, marrow stroma (hematopoietic lineage support), tendonligament, fat, etc. 4<10 This multipotency and a specific set of cell surface antigens (C73, CD90, CD105, etc) have been used as definition for MSCs. 11 The hypothesis, based on cell culture experiments, was that MSCs in situ provide replacement units for injured or expiring differentiated cells in various mesenchymal tissues. In addition, vigorous and extensive use of MSCs in engineered tissues has been and continues to be aggressively explored. 12<15 From the efforts of my laboratory and those of others, I can say that there are no MSC-derived engineered tissues that have been successfully differentiated and implanted to provide therapeutic benefits. Moreover, this tissue-specific differentiation is now understood to require a different spectrum of multiple growth factors in sequential exposure to generate, for example, ear, nose, throat, sternal, hip, knee, and ankle cartilage, 16, 17 which are all quite different in identity, relative quantity of molecular constituents, and mechanical functionality. The management of multipotent progenitors generated by a number of newer technologies is now being actively pursued using this sequential exposure logic 18<20 but is outside the context of this treatise.
The new
Information firmly establishing that all MSCs are derived from perivascular cellsVpericytesVis now available. 21<23 Thus, every vascularized tissue in the body has MSCs by virtue of the fact that all blood vessels are covered with pericytes. These pericytes are released from their anchorage in the extracellular matrix (ECM) surrounding each blood vessel or sinusoid to generate local MSCs upon injury or inflammation. These newly released MSCs are activated by the local microenvironment and react by secreting two sets of bioactive molecules. From the front of MSCs, curtains of molecules inhibit interrogating immune cells from entering the injury field (the first line of defense against the establishment of autoimmune reactions). 24<28 From the back of locally activated MSCs, another complex set of factors are secreted, which help establish a regenerative microenvironment. These trophic factors 27 (a) inhibit ischemia-caused apoptosis; (b) inhibit scar formation; (c) stimulate angiogenesis; and (d) stimulate mitosis of tissue-specific progenitors. 28 Given these functional parameters, I now propose to redefine MSC as a Bmedicinal signaling cell[ that functions as a drug store at sites of tissue injury or inflammation. 28 Given such information, how do these newly described properties relate to women's health?
MENSTRUAL CYCLE AND MSCS
Several reports have clearly documented that large quantities of MSCs can be isolated from menstrual blood. 29<31 These MSCs are released from uterine wall vessels as uterine tissue replaces itself and regenerates its endometrial lining. Whether the number and timing of released MSCs affect the severity and duration of menstrual flow has not been investigated (a suggestion). Indeed, I would further suggest that perhaps the delivery of a bolus of exogenous MSCs into the uterine lining at the right time might speed healing and repair/ regeneration of the uterine wall and potentially decrease the severity of menstruation. The premise for this suggestion is that exogenously supplied MSCs might provide paracrine factors that decrease pain and enhance reestablishment of functional and unbroken blood vessels in the regenerating muscular tissue of the uterus.
In cases of urinary incontinence and fecal incontinence, which are prevalent in women, preliminary data from animal models and humans indicate that exogenously provided MSCs profoundly enhance the regeneration of afflicted tissues to restore normal function and to cure these maladies. 32<36 I stress that any tissue condition that can benefit from immune modulation, trophic activity, or a regenerative microenvironment is a candidate for MSC-based therapy. Indeed, a search of the website ClinicalTrials.gov for MSC-based trials lists more than 450 such trials with an amazing array of clinical symptoms that all have an immune component and a regenerative component. Surprisingly, very few of these studies focused on issues of women's health care.
THERAPEUTIC USES OF MSCS
As an example of the therapeutic use of either autologous or allogeneic MSCs, consider acute or chronic cardiac conditions. For acute myocardial infarct, culture-expanded marrow-derived allogeneic MSCs are administered within 48 hours of the first symptoms of acute myocardial infarct. Published results of a phase II clinical trial indicated that considerable protection of heart tissue is achieved with infusion of allogeneic MSCs (Osiris Therapeutics Inc and Amado et al 37 ) . Likewise, very positive research has been reported by Cytori Inc and Quevedo et al 38 using autologous MSC preparation from adipose tissue. In this context, injecting MSCs into osteoarthritic joints or spinal discs yielded positive outcomes (Osiris Therapeutics Inc and Ghosh et al 39 ) . Thus, in cardiac and orthopedic sites, exogenous MSCs seem to have profound therapeutic outcomes, although no phase III trial has yet to be completed.
MENOPAUSE
No study has related MSC function to the hormone status of an individual. Specifically, how does loss of circulating estrogen affect pericyte titers and MSC function? As a first step in this regard, one set of experiments has been conducted to determine whether MSCs from male and female donors are different. As a first step, the proliferative capacities of marrow MSCs from male and female donors were compared. Female MSCs divide faster and undergo more population doubling compared with male MSCs (unpublished observations, D. Lennon et al). Figure 2 shows the schematic protocol for these experiments. The most stringent test in such a comparison is starting the cultures with equal numbers of MSCs derived from both male and female donors. Data in Figure 2 document that, by the end of 1 week in culture, female MSCs have almost completely taken over the cultures. The simplest explanation for this is the fact that this MSC culture expansion has been optimized 40 using selected batches of fetal calf serum (FCS). Such serum, of course, has huge levels of estrogen provided by the pregnant mother. This estrogen in FCS preferentially supports the expansion of female MSCs.
Whether male MSCs are intrinsically different from female MSCs has not been determined. This comparison would be extremely difficult to assess because the expressional capacity (genome-controlled) of every donor MSC is quantitatively different. 41 Moreover, the FCS-supplemented growth medium for cell cultureYproduced MSCs is quite influential on the observed secretory and differentiation properties of MSCs. 40, 42 In most ongoing clinical trials testing allogeneic MSCs for safety, potency, and efficacy, the starting marrow has been obtained (mostly) from 20-to 30-year-old men. 43,43a These young donor MSCs have been culture-expanded in selected lots of FCS, suggested to be optimal for MSC expansion with retention of multipotency. An exception is the isolation and expansion of MSC-like cells derived from discarded full-term placentas. 44, 45 Will these placental MSCs prove to be superior to marrowderived male MSCs?
OSTEOTROPHIC CANCERS Breast cancer and melanoma are not only frequent among women but are also known to metastasize to bone. 46, 47 If every blood vessel in the body is covered with pericytes, how do metastasizing cancer cells get through the basement membrane ECM surrounding all blood vessels and past the covering and ECM-embedded pericytes? Figure 3 presents the current research hypothesisVthat platelet-derived growth factor BB anchors pericyte on the basement membrane perivascular ECM. 48 As melanoma cells bridge the endothelial layer, platelets are broken, releasing their contents, including large amounts of platelet-derived growth factor BB. 3 . Mechanistic candidates. The working hypothesis on how a melanoma cell crosses the endothelial/basement barrier to actively establish metastasis in bone. Evidence suggests that mesenchymal stem cell (MSC)/pericyte secretes SDF-1/CXCL12, causing melanoma cells to slide into range by virtue of its CXCR4. The release of platelet-derived growth factor BB (PDGF-BB) by platelets surrounding circulating melanoma cells detaches pericyte from its anchorage controlled by platelet-derived growth factor receptor A (PDGFR-A) and by pericellular heparin sulfate binding of PDGF-BB to pericytes of PDGFR-A. Because both melanoma cell and MSC/pericyte have CD146 on their outer membranes, a CD146 homodimer is formed, and melanoma cell/MSC are brought into bone stroma as a coupled pair. EC, BM, KO. 42, 50 Melanoma cells are attracted to pericytes by their secretion of SDF-1 49 and, importantly, melanoma cells bind to MSCs/ pericytes via a CD146 homodimer, 50 coupling on both cells' outer membrane. This bound couple is now incorporated into bone stroma, where melanoma cells corrupt the secretory capacity of MSCs to provide both angiogenic and proliferative stimulants. The end result are the establishment and expansion of melanoma metastasis in bone, resulting in osteolytic events, bone loss and fracture, and pain. This detailed chemistry provides a platform for searching for inhibitory molecules for osteotrophic metastatic melanoma and breast cancers with MSC as central mediator. 42 
MSCS AND WOMEN'S HEALTH
The basic and clinical science of MSCs is a rapidly emerging field. Insufficient energy and resources have been considered in applying cell-based therapies to prevent and cure maladies central to women's health. As a speculative example, if MSCs are antiscarring, can they be used to inhibit the expansion ofVor indeed shrinkVuterine fibroids? Small facial scars have disappeared in women receiving MSC fat injections for cosmesis (wrinkle reduction). 52 This suggestion must first be approached in suitable preclinical models before proper Food and Drug AdministrationYapproved clinical trials (investigatorinitiated or commercially initiated). 51 The future for cell-based therapies in women's health is an open door waiting for creative, reasonable, and testable hypotheses, followed by new clinical logics and medical solutions for women.
CONCLUSIONS
The new science and clinical use of both endogenously and exogenously supplied MSCs will have a huge impact on the practice of medicine. Numerous problems associated with women's health should be addressed using this cell-based therapeutic approach. Although women have used MSCbased technologies for cosmetic indications for the last 10 to 15 years, it would seem reasonable to suggest that more serious clinical symptoms could now be addressed using MSCbased therapies.
